公开(公告)号：US20130116148A1

公开(公告)日：2013-05-09

申请号：US13805170

申请日：2011-05-17

申请人： Tomoyoshi Soga ,  Masahiro Sugimoto ,  Makoto Suematsu ,  Takafumi Saito ,  Sumio Kawata

发明人： Tomoyoshi Soga ,  Masahiro Sugimoto ,  Makoto Suematsu ,  Takafumi Saito ,  Sumio Kawata

IPC分类号： G01N33/68

CPC分类号： G01N33/576 ,  G01N33/5767 ,  G01N2800/085 ,  G01N2800/7009

摘要： Disclosed is a method for promptly identifying a liver disease. A normal person or a liver disease such as drug-induced liver injury, asymptomatic hepatitis B carrier, chronic hepatitis B, hepatitis C with persistently normal ALT, chronic hepatitis C, cirrhosis type C, hepatocellular carcinoma, simple steatosis, or non-alcoholic steatohepatitis is identified by measuring the concentration of a γ-Glu-X (wherein X represents an amino acid or an amine) peptide or the level of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value.

摘要翻译： 公开了一种迅速鉴别肝脏疾病的方法。 正常人或肝脏疾病如药物诱导的肝损伤，无症状乙型肝炎携带者，慢性乙型肝炎，丙型肝炎持续ALT正常，慢性丙型肝炎，C型肝硬化，肝细胞癌，单纯脂肪变性或非酒精性脂肪性肝炎 通过测量γ-Glu-X（其中X表示氨基酸或胺）肽的浓度或血液中AST或ALT的水平进行鉴定，并且基于测量值进行多重逻辑回归 。

公开(公告)号：US20110256561A1

公开(公告)日：2011-10-20

申请号：US13140713

申请日：2009-11-26

申请人： Tomoyoshi Soga ,  Masahiro Sugimoto ,  Makoto Suematsu ,  Masashi Honma ,  Takehito Yamamoto ,  Hiroshi Suzuki

发明人： Tomoyoshi Soga ,  Masahiro Sugimoto ,  Makoto Suematsu ,  Masashi Honma ,  Takehito Yamamoto ,  Hiroshi Suzuki

IPC分类号： G01N33/68 ,  C07D233/64 ,  C12M1/40 ,  C07D209/20 ,  G01N33/53 ,  C12Q1/02 ,  C07C229/26 ,  C07C229/36

CPC分类号： G01N33/487 ,  C07K5/0215 ,  G01N33/497 ,  G01N33/576 ,  G01N33/6812 ,  G01N33/6893 ,  G01N2800/08 ,  G01N2800/60

摘要： A normal person (i.e. a control) and liver diseases such as drug induced liver injury, an asymptomatic hepatitis B carrier, an asymptomatic hepatitis C carrier, chronic hepatitis B, chronic hepatitis C, liver cancer, a nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and simple steatosis (SS) are identified by measuring the concentrations of γ-Glu-X (X represents an amino acid or an amine) peptides or the levels of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value.

摘要翻译： 正常人（即对照）和肝脏疾病如药物诱发的肝损伤，无症状乙型肝炎携带者，无症状丙型肝炎携带者，慢性乙型肝炎，慢性丙型肝炎，肝癌，非酒精性脂肪性肝病（NAFLD） 通过测量血液中γ-Glu-X（X代表氨基酸或胺）肽的浓度或AST或ALT的水平，进行例如，通过测定非酒精性脂肪性肝炎（NASH）和简单脂肪变性（SS） ，基于测量值的多重逻辑回归。

公开(公告)号：US20090029409A1

公开(公告)日：2009-01-29

申请号：US12161203

申请日：2007-01-16

申请人： Tomoyoshi Soga ,  Makoto Suematsu

发明人： Tomoyoshi Soga ,  Makoto Suematsu

IPC分类号： C12Q1/06

CPC分类号： G01N33/6893 ,  G01N2430/00 ,  G01N2500/00 ,  G01N2800/00

摘要： Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

摘要翻译： 提供了能够容易且快速地检测活体上的氧化应激的生物标志物，并且能够通过药物给药预防组织损伤或细胞坏死，并且其是研究各种药剂的毒性和药代动力学的有力标记。 通过使用诸如毛细管电泳 - 质谱仪的分析仪，通过测量根据生物样品中还原型谷胱甘肽（GSH）浓度的变化的血液变化的眼睛液的血液浓度来测定氧化应激。 此外，通过在氧化应激条件下向非人动物施用抗氧化应激候选试剂，测定眼酸的血药浓度，评价眼酸浓度的降低程度来筛选抗氧化应激剂。

公开(公告)号：US07964177B2

公开(公告)日：2011-06-21

申请号：US12161203

申请日：2007-01-16

申请人： Tomoyoshi Soga ,  Makoto Suematsu

发明人： Tomoyoshi Soga ,  Makoto Suematsu

IPC分类号： A61K49/00 ,  G01N33/00

CPC分类号： G01N33/6893 ,  G01N2430/00 ,  G01N2500/00 ,  G01N2800/00

摘要： Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

摘要翻译： 提供了能够容易且快速地检测活体上的氧化应激的生物标志物，并且能够通过药物给药预防组织损伤或细胞坏死，并且其是研究各种药剂的毒性和药代动力学的有力标记。 通过使用诸如毛细管电泳 - 质谱仪的分析仪，通过测量根据生物样品中还原型谷胱甘肽（GSH）浓度的变化的血液变化的眼睛液的血液浓度来测定氧化应激。 此外，通过在氧化应激条件下向非人动物施用抗氧化应激候选试剂，测定眼酸的血药浓度，评价眼酸浓度的降低程度来筛选抗氧化应激剂。

公开(公告)号：US08309056B2

公开(公告)日：2012-11-13

申请号：US13092420

申请日：2011-04-22

申请人： Tomoyoshi Soga ,  Makoto Suematsu

发明人： Tomoyoshi Soga ,  Makoto Suematsu

IPC分类号： A61K49/00 ,  G01N33/48 ,  G01N33/00

CPC分类号： G01N33/6893 ,  G01N2430/00 ,  G01N2500/00 ,  G01N2800/00

摘要： Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

摘要翻译： 提供了能够容易且快速地检测活体上的氧化应激的生物标志物，并且能够通过药物给药预防组织损伤或细胞坏死，并且其是研究各种药剂的毒性和药代动力学的有力标记。 通过使用诸如毛细管电泳 - 质谱仪的分析仪，通过测量根据生物样品中还原型谷胱甘肽（GSH）浓度的变化的血液变化的眼睛液的血液浓度来测定氧化应激。 此外，通过在氧化应激条件下向非人动物施用抗氧化应激候选试剂，测定眼酸的血药浓度，评价眼酸浓度的降低程度来筛选抗氧化应激剂。

公开(公告)号：US20070256935A1

公开(公告)日：2007-11-08

申请号：US11660676

申请日：2005-08-24

申请人： Masahiro Sugimoto ,  Tomoyoshi Soga ,  Masaru Tomita

发明人： Masahiro Sugimoto ,  Tomoyoshi Soga ,  Masaru Tomita

IPC分类号： B01D57/02

CPC分类号： G01N27/447

摘要： When the migration time of a low molecular weight compound having an unknown migration time in microchip electrophoresis, capillary electrophoresis, or a capillary electrophoresis mass spectrometer is predicted, first, with respect to a substance having a known electrophoretic migration time, characteristic quantities (descriptors) thereof which can be numerically expressed from a structure thereof are computed to predict the relation between the characteristic quantities (descriptors) and the migration time; the migration times of some substances are measured by electrophoresis or an electrophoresis mass spectrometer to learn about the relation; and using the learnt result, the migration time of the substance having an unknown migration time in the electrophoresis or electrophoresis mass spectrometer is predicted from the structure thereof.

摘要翻译： 当预测在微芯片电泳，毛细管电泳或毛细管电泳质谱仪中具有未知迁移时间的低分子量化合物的迁移时间时，首先，关于具有已知电泳迁移时间的物质，特征量（描述符） 计算其数值表示的结构，以预测特征量（描述符）与迁移时间之间的关系; 通过电泳或电泳质谱仪测量某些物质的迁移时间，以了解关系; 并且使用所获得的结果，从其结构可以预测在电泳或电泳质谱仪中具有未知迁移时间的物质的迁移时间。

公开(公告)号：US20100210023A1

公开(公告)日：2010-08-19

申请号：US12585598

申请日：2009-09-18

申请人： David T.W. Wong ,  Masaru Tomita ,  Masahiro Sugimoto ,  Akiyoshi Hirayama ,  Tomoyoshi Soga

发明人： David T.W. Wong ,  Masaru Tomita ,  Masahiro Sugimoto ,  Akiyoshi Hirayama ,  Tomoyoshi Soga

IPC分类号： G01N33/68 ,  G01N33/00 ,  G01N27/26 ,  B01D57/02

CPC分类号： G01N33/57488 ,  G01N33/57407 ,  G01N2800/18 ,  Y10T436/145555 ,  Y10T436/17 ,  Y10T436/173845 ,  Y10T436/20

摘要： The present invention provides a novel oral cancer and periodontal disease salivary metabolome for use in the diagnosis or for providing a prognosis for oral cancer and periodontal disease in an individual. The present invention also provides novel methods of diagnosing or providing a prognosis for oral cancer or periodontal disease by detecting metabolites found in the saliva of an individual. Finally, the present invention provides kits for the detection of salivary metabolites useful in the diagnosis or prognosis of oral cancer and periodontal disease in an individual.

摘要翻译： 本发明提供了一种用于诊断或提供个体中口腔癌和牙周病的预后的新型口腔癌和牙周病唾液代谢素。 本发明还提供了通过检测个体唾液中发现的代谢物来诊断或提供口腔癌或牙周病预后的新方法。 最后，本发明提供了用于检测个体中可用于口腔癌和牙周病诊断或预后的唾液代谢物的试剂盒。

公开(公告)号：US20070172825A1

公开(公告)日：2007-07-26

申请号：US10588923

申请日：2005-02-08

申请人： Masaru Tomita ,  Aya Itoh ,  Tomoyoshi Soga

发明人： Masaru Tomita ,  Aya Itoh ,  Tomoyoshi Soga

IPC分类号： C12Q1/68

CPC分类号： G01N33/5023 ,  G01N33/6848

摘要： [Problems to be Solved] An objective of the present invention is to provide methods and kits for identifying the function of a functionally unknown gene product, and methods and kits for identifying a binding substance, which are widely applicable to numerous organism species. [Means to Solve the Problems] At least one gene product is added to a compound cocktail such as a metabolic compound cocktail containing all of the metabolic substances, coenzymes, and such involved in a certain metabolic system, the mixture is reacted, and then a change occurred in the compound cocktail is detected, thereby making it possible to identify the function of the gene product or a substance that binds thereto.

摘要翻译： [待解决的问题]本发明的目的是提供用于鉴定功能未知基因产物的功能的方法和试剂盒，以及用于鉴定结合物质的方法和试剂盒，其广泛适用于许多生物种类。 [解决问题的手段]将至少一种基因产物加入到混合物混合物中，例如含有所有代谢物质，辅酶等参与某种代谢系统的代谢化合物混合物，混合物反应，然后 检测到化合物混合物中发生的变化，从而可以鉴定与其结合的基因产物或物质的功能。

公开(公告)号：US20090256066A1

公开(公告)日：2009-10-15

申请号：US11991407

申请日：2006-07-31

申请人： Tomoyoshi Soga ,  Yuji Kakazu ,  Masaru Tomita ,  Takamasa Ishikawa

发明人： Tomoyoshi Soga ,  Yuji Kakazu ,  Masaru Tomita ,  Takamasa Ishikawa

IPC分类号： G01D18/00 ,  B01D59/44

CPC分类号： G01N30/7233 ,  G01N2030/626

摘要： In a mass spectrometry system designed so as to feed a solution to an interface 20 between a separation analysis instrument (10) and amass spectrometer 50, an internal standard for mass calibration is mixed with the solution (an electrophoresis buffer solution 16 of capillary electrophoresis apparatus 10, a mobile phase of liquid chromatograph or a sheath solution for obtaining an electrical contact of the separation analysis instrument with the mass spectrometer), and a detected mass is calibrated. Thereby, it is possible to simply and conveniently calibrate the mass of a substance to be measured without using a calibration spray device or employing a post column introduction method.

摘要翻译： 在设计为将分析分析仪器（10）和聚焦光谱仪50之间的界面20供给溶液的质谱系统中，将质量校准用内标与溶液（毛细管电泳仪的电泳缓冲溶液16 10，用于获得分离分析仪器与质谱仪的电接触的液相色谱或流动相的流动相）和校准的质量。 因此，可以在不使用校准喷雾装置或采用后柱引入方法的情况下简单且方便地校准要测量的物质的质量。

公开(公告)号：US08709816B2

公开(公告)日：2014-04-29

申请号：US13393091

申请日：2010-09-03

申请人： Takaaki Abe ,  Tomoyoshi Soga

发明人： Takaaki Abe ,  Tomoyoshi Soga

IPC分类号： G01N33/48 ,  G01N33/00

CPC分类号： G01N33/6893 ,  G01N2800/347

摘要： The present invention relates to a method for diagnosing, and treating renal disease in a patient by having a test performed for detecting or quantifying one or more renal disease markers present in a test blood sample from the patient; and administering treatment to improve renal function. In particular embodiments, the test performed quantifies cis-aconitate, and the patient is identified as having the renal disease when a concentration of cis-aconitate present in the patient's test blood sample is higher than that of a control. Methods of the present invention can allow diagnosis and treatment of patients with early stage renal disease, such as early stage renal failure. Another aspect of the present invention relates to methods for screening for a prophylactic/therapeutic agent for treating renal disease using one or more renal disease markers.

摘要翻译： 本发明涉及通过进行用于检测或定量来自患者的测试血液样品中存在的一种或多种肾脏疾病标志物的测试来诊断和治疗患者的肾脏疾病的方法; 并进行治疗以改善肾功能。 在具体实施方案中，进行的测试量化顺式乌头酸，并且当患者测试血液样品中存在的顺式乌头酸浓度高于对照组时，患者被鉴定为具有肾脏疾病。 本发明的方法可以允许诊断和治疗患有早期肾病的早期肾衰竭患者。 本发明的另一方面涉及使用一种或多种肾脏疾病标记物筛选用于治疗肾脏疾病的预防/治疗剂的方法。